American Heart Journal
Volume 159, Issue 2 , Pages 159-169.e4 , February 2010

Effectiveness and safety of drug-eluting stents in vein grafts: A meta-analysis

  • Dominique Joyal, MD

      Affiliations

    • Division of Cardiology, Jewish General Hospital, Montreal, Quebec, Canada
    • ,
  • Kristian B. Filion, PhD

      Affiliations

    • Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
    • Division of Clinical Epidemiology, McGill University Health Center, Montreal, Quebec, Canada
    • Division of Clinical Epidemiology, Jewish General Hospital, Montreal, Quebec, Canada
    • ,
  • Mark J. Eisenberg, MD, MPH

      Affiliations

    • Division of Cardiology, Jewish General Hospital, Montreal, Quebec, Canada
    • Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
    • Division of Clinical Epidemiology, Jewish General Hospital, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Mark J. Eisenberg, MD, MPH, FACC, FAHA, Divisions of Cardiology and Clinical Epidemiology, Jewish General Hospital/McGill University, 3755 Cote Ste. Catherine Rd/Suite A-118, Montreal, Quebec, Canada H3T 1E2.

Received 13 July 2009 ,Accepted 12 November 2009.

References 

  1. Farb A, Boam AB. Stent thrombosis redux—the FDA perspective. N Engl J Med. 2007;356:984–987
  2. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297:1992–2000
  3. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342–352
  4. Carlsson J, James SK, Lindbäck J, et al. Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria. J Am Coll Cardiol. 2009;53:1389–1398
  5. Applegate RJ, Sacrinty MT, Kutcher MA, et al. “Off-label” stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2008;51:607–614
  6. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896–1900
  7. Bax L, Yu LM, Ikeda N, et al. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol. 2006;6:
  8. Bax L, Yu LM, Ikeda N, et al. MIX: comprehensive free software for meta-analysis of causal research data. Version 1.7. http://mix-for-meta-analysis.info2008;
  9. Okabe T, Lindsay J, Buch AN, et al. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol. 2008;102:530–534
  10. Vignali L, Saia F, Manari A, et al. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro Regionale AngiopLastiche Emilia-Romagna registry). Am J Cardiol. 2008;101:947–952
  11. Ellis SG, Kandzari D, Kereiakes DJ, et al. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. J Invasive Cardiol. 2007;19:404–409
  12. Ramana RK, Ronan A, Cohoon K, et al. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv. 2008;71:886–893
  13. Gioia G, Benassi A, Mohendra R, et al. Lack of clinical long-term benefit with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv. 2008;72:13–20
  14. Lee MS, Shah AP, Aragon J, et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv. 2005;66:507–511
  15. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol. 2005;45:989–994
  16. Applegate RJ, Sacrinty M, Kutcher M, et al. Late outcomes of drug-eluting versus bare metal stents in saphenous vein grafts: propensity score analysis. Catheter Cardiovasc Interv. 2008;72:7–12
  17. Hoffmann R, Hamm C, Nienaber CA, et al. for the German Cypher Registry. Implantation of sirolimus-eluting stents in saphenous vein grafts is associated with high clinical follow-up event rates compared with treatment of native vessels. Coron Artery Dis. 2007;18:559–564
  18. Minutello RM, Bhagan S, Sharma A, et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol. 2007;20:458–465
  19. Bansal D, Sachdeva R, Mehta JL. Percutaneous intervention in saphenous vein bypass graft disease: case against the use of drug-eluting stents. J Am Coll Cardiol. 2008;51:970–971
  20. Chu WW, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol. 2006;97:34–37
  21. Kaplan S, Barlis P, Kiris A, et al. Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions. Acute Card Care. 2008;10:88–92
  22. Jeger RV, Schneiter S, Kaiser C, et al. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. Cardiology. 2009;112:49–55
  23. Wöhrle J, Nusser T, Kestler HA, et al. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol. 2007;96:70–76
  24. Lozano I, García-Camarero T, Carrillo P, et al. Comparison of drug-eluting and bare metal stents in saphenous vein grafts. Immediate and long-term results. Rev Esp Cardiol. 2009;62:39–47
  25. Assali A, Raz Y, Vaknin-Assa H, et al. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions. EuroIntervention. 2008;4:108–114
  26. van Twisk PH, Daemen J, Kukreja N, et al. Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts. EuroIntervention. 2008;4:311–317
  27. Vermeersch P, Agostoni P, Verheye S, et al. DELAYED RRISC (Death and Events at Long-term follow-up AnalYsis: Extended Duration of the Reduction of Restenosis In Saphenous vein grafts with Cypher stent) Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. J Am Coll Cardiol. 2007;50:261–267
  28. Brilakis ES, Lichtenwalter C, de Lemos JA, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol. 2009;53:919–928
  29. Sarjeant JM, Rabinovitch M. Understanding and treating vein graft atherosclerosis. Cardiov Pathology. 2002;11:263–271
  30. Ratliff NB, Myles JL. Rapidly progressive atherosclerosis in aortocoronary saphenous vein grafts. Possible immune-mediated disease. Arch Pathol Lab Med. 1989;113:772–776
  31. Cross KS, Davies MG, el Sanadiki MN, et al. Long-term human vein graft contractility and morphology: a functional and histopathological study of retrieved coronary vein grafts. Br J Surg. 1994;81:699–705
  32. AV Sterpetti A, Cucina B, Randone R, et al. Growth factor production by arterial and vein grafts: relevance to coronary artery bypass grafting. Surgery. 1996;120:460–467
  33. Ge L, Iakovou I, Cosgrave J, et al. Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J. 2005;26:1056–1062
  34. Commeau P, Barragan PT, Roquebert PO, et al. ISR II study: a long-term evaluation of sirolimus-eluting stent in the treatment of patients with in-stent restenotic native coronary artery lesions. Catheter Cardiovasc Interv. 2005;66:158–162
  35. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol. 2006;48:2423–2431

 Dr Eisenberg is a Chercheur-National of the Fonds de la Recherche en Santé du Quebec. Dr Filion received financial support from the Faculty of Medicine of McGill University, the Research Institute of the McGill University Health Centre, and the Department of Medicine of the McGill University Health Center.

 Conflict of interest/disclosure: none.

PII: S0002-8703(09)00901-6

doi: 10.1016/j.ahj.2009.11.021

American Heart Journal
Volume 159, Issue 2 , Pages 159-169.e4 , February 2010

Article Tools

* Image Usage & Resolution